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Pour en savoir plus
Kotsopoulos J, Librach CL, Lubinski J (2008) Infertility, treatment of 
infertility, and the risk of breast cancer among women with BRCA1 and 
BRCA2 mutations: a case-control study. Cancer Causes Control 19: 1111-9
Women with a breast cancer susceptibility gene 1 (BRCA1) or breast cancer 
susceptibility gene 2 (BRCA2) mutation are at increased risk for developing 
breast and ovarian cancer. Various reproductive and hormonal factors have been 
shown to modify the risk of breast cancer. Th ese studies suggest that estrogen 
exposure and deprivation are important in the etiology of hereditary cancer. Many 
patients are interested in the possibility of an adverse eff ect of fertility treatment 
on breast cancer risk. It is important to evaluate whether or not infertility per se 
or exposure to fertility medications increase the risk of breast cancer in genetically 
predisposed women.
We conducted a matched case-control study of 1,380 pairs of women with 
a BRCA1 or BRCA2 mutation to determine if a history of infertility, the use of 
fertility medications, or undergoing in vitro fertilization (IVF) were associated 
with and increased the risk of breast cancer.
Sixteen percent of the study subjects reported having experienced a fertility 
problem and 4% had used a fertility medication. Women who had used a fertility 
medication were not at signifi cantly increased risk of breast cancer (odds ratio 
[OR] = 1.21; 95% confi dence interval [CI] = 0.81-1.82) compared to non-users. 
Furthermore, there was no risk associated with a history of use of a fertility 
medication when the subjects were stratifi ed by parity: (OR  = 1.29; 95% 
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CI = 0.83-2.01 for nulliparous women and OR = 0.81; 95% CI = 0.30-2.22 
for parous women).
Th e results of this study suggest that the use of fertility medications does not 
adversely aff ect the risk of breast cancer among BRCA mutation carriers. Given 
the small sizes of the exposed subgroups, these fi ndings should be interpreted 
with caution and confi rmatory studies are required.
Pappo I, Lerner-Geva L, Halevy A (2008) Th e possible association between 
IVF and breast cancer incidence. Ann Surg Oncol 15: 1048-55
Th e possible association between ovulation-inducing drugs and breast cancer 
development has been debated. Our aim was to evaluate the incidence of breast 
cancer in a cohort of women exposed to in vitro fertilization (IVF).
A retrospective cohort analysis was performed by linkage of the computerized 
database of all women treated at the IVF Unit at Assaf Harofeh Medical Center 
between 1986 and 2003, and the Israeli National Cancer Registry. Th e standardized 
incidence ratio (SIR) was computed as the ratio between the observed number 
of breast cancer cases and the expected cases, adjusted for age and continent of 
birth, in the general population. Tumor characteristics of the IVF patients were 
studied by reviewing original medical records.
35 breast carcinomas were diagnosed among 3,375 IVF-treated women, 
compared to 24.8 cases expected (SIR = 1.4; 95% CI 0.98-1.96). Age >or=40 years 
at IVF treatment (SIR = 1.9; 95% CI 0.97-3.30), hormonal infertility (SIR 
= 3.1; 95% CI 0.99-7.22), and >or=4 IVF cycles (SIR = 2.0; 95% CI 1.15-3.27) 
were found to be risk factors to develop breast cancer compared to the general 
population. Multivariate analysis revealed that women who underwent >or=4 IVF 
cycles compared to those with one to three cycles were at risk to develop breast 
cancer, although not signifi cantly (SIR = 1.9; 95% CI 0.95-3.81). Of IVF-treated 
women 85% had ER(+) tumors and 29% had positive family history.
A possible association between IVF therapy and breast cancer development 
was demonstrated, especially in women >or=40 years of age. Th ese preliminary 
fi ndings need to be replicated in other cohort studies.
Orgéas CC, Sanner K, Hall P (2009) Breast cancer incidence after hormonal 
infertility treatment in Sweden: a cohort study. Am J Obstet Gynecol 200: 
72.e1-7
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To assess the impact of infertility treatment with causes of infertility on incidence 
of breast cancer.
Historical prospective cohort study of 1135 women attending major university 
clinics for treatment of infertility in Sweden, 1961-1976. Women were classifi ed as 
users of clomiphene citrate or gonadotropins, or a combination of both therapies. 
Standardized incidence ratios were calculated to estimate relative risk of breast 
cancer.
We observed 54 cases of breast cancer during 1961-2004, which did not 
signifi cantly exceed those expected. Users of high-dose clomiphene citrate 
had an almost 2-fold increased risk (standardized incidence ratio, 1.90; 95% 
confi dence interval, 1.08-3.35). Th is association was more pronounced among 
women referred for nonovulatory factors, with 3-fold increased risk (standardized 
incidence ratio, 3.00; 95% confi dence interval, 1.35-6.67).
No overall increased risk for breast cancer was shown with infertility treatment. 
Women with nonovulatory causes treated with high-dose clomiphene citrate 
therapy may have an elevated risk for breast cancer.
Lerner-Geva L, Keinan-Boker L, Blumstein T (2006) Infertility, ovulation 
induction treatments and the incidence of breast cancer  – a historical 
prospective cohort of Israeli women. Breast Cancer Res Treat 100: 201-12
Ovulation induction drugs may be associated with increased breast cancer risk. 
Results so far have been inconclusive.
To evaluate the association between infertility, exposure to ovulation induction 
drugs and the incidence of breast cancer.
Historical prospective cohort and nested case-control study.
Institutional practice: About 5,788 women attending fi ve infertility centers 
in Israel between 1964 and 1984. Intention: Abstracting of medical records and 
telephone interviews.
Breast cancer incidence was determined through linkage with the National 
Cancer Registry database. Standardized incidence ratios (SIRs) and 95% 
confi dence intervals were computed by comparing the observed to the expected 
cancer rates in the general population. In addition, a nested case-control study 
within the cohort was performed with interviews of breast cancer cases and two 
matched controls.
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Th e study cohort included 120,895 women years of follow-up. Compared 
to 115.2 expected breast cancer cases, 131 cases were observed (SIR = 1.1; 95% 
CI 0.9-1.4). Risk for breast cancer was signifi cantly higher for women treated 
with clomiphene citrate (SIR = 1.4; 95% CI 1.0-1.8). Similar results were noted 
when comparisons were carried out between treated and untreated women, and 
when multivariate models were applied. In the nested case-control study, higher 
cycle index (OR = 2.2; 95% CI 1.0-4.8) and treatment with clomiphene citrate 
(OR=2.7; 95% CI 1.3-5.7) were associated with higher risk for breast cancer.
Infertility and usage of infertility drugs in general are not associated with 
increased risk for breast cancer. However, for infertile women treated with 
clomiphene citrate, breast cancer risk is elevated.
Oktay K, Kim JY, Barad D (2010) Association of BRCA1 mutations with 
occult primary ovarian insuffi  ciency: a possible explanation for the link 
between infertility and breast/ovarian cancer risks. J Clin Oncol 28: 240-4
Germline mutations in BRCA genes are associated with breast and ovarian cancer 
susceptibility. Because infertility is associated with breast and ovarian cancer risks, 
we hypothesized that the mutations in the BRCA gene may be associated with 
low response to fertility treatments.
We performed ovarian stimulation in 126 women with breast cancer by using 
letrozole and gonadotropins for the purpose of fertility preservation by embryo 
or oocyte cryopreservation. As surrogates of ovarian reserve, the oocyte yield and 
the incidence of low response were compared with ovarian stimulation according 
to BRCA mutation status.
Of the 82 women who met the inclusion criteria, 47 women (57%) had 
undergone BRCA testing, and 14 had a mutation in BRCA genes, of which 
two were of clinically undetermined signifi cance. In BRCA mutation-positive 
patients, low ovarian response rate was signifi cantly higher compared with BRCA 
mutation-negative patients (33.3 v 3.3%; P = .014) and with BRCA-untested 
women (2.9%; P = .012). All BRCA mutation-positive low responders had BRCA1 
mutations, but low response was not encountered in women who were only 
BRCA2 mutation positive. Compared with controls, BRCA1 mutation- but not 
BRCA2 mutation-positive women produced lower numbers of eggs (7.4 [95% 
CI, 3.1 to 17.7] v 12.4 [95% CI, 10.8 to 14.2]; P = .025) and had as many as 
38.3 times the odds ratio of low response (95% CI, 4.1 to 353.4; P = .001).
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BRCA1 mutations are associated with occult primary ovarian insuffi  ciency. 
Th is fi nding may, at least in part, explain the link between infertility and breast/
ovarian cancer risks.
Quinn GP, Vadaparampil ST, Tollin S (2010) BRCA carriers’ thoughts on 
risk management in relation to preimplantation genetic diagnosis and 
childbearing: when too many choices are just as diffi  cult as none. Fertil 
Steril 94: 2473-5
Women with a BRCA mutation have unique concerns about childbearing and 
future fertility. In a focus group conducted among unaff ected carriers, the majority 
of women held positive attitudes toward preimplantation genetic diagnosis to 
reduce transmission to future off spring and further identifi ed unmet needs for 
education and support for decision making.
Ormondroyd E, Donnelly L, Moynihan C (2012) Attitudes to reproductive 
genetic testing in women who had a positive BRCA test before having 
children: a qualitative analysis Eur J Hum Genet 20: 4-10
Th e scope of conditions for which preimplantation genetic diagnosis (PGD) is 
licensed has recently been expanded in the United Kingdom to include genetic 
predisposition to adult-onset cancer. Th is qualitative interview study explores 
reproductive decision making, knowledge of and attitudes to reproductive genetic 
testing (prenatal diagnosis and PGD) with 25 women aged 18-45 years who 
received a positive BRCA test in the United Kingdom before having children. In 
this cohort of younger women, BRCA testing was motivated by risk management 
decisions; for some, BRCA status has aff ected their later decisions about having 
children. Th e perceived severity of hereditary breast/ovarian cancer (HBOC) 
infl uences thoughts about passing on the mutation to children and willingness to 
consider reproductive genetic testing, but most participants do not believe HBOC 
is a condition for which pregnancy termination is justifi ed. PGD is considered 
more acceptable and advantageous because it would prevent transmission to 
future generations, but women have concerns about selecting embryos and the 
fact that they and aff ected family members would not have been selected. Women 
would also be deterred by the need to undergo in vitro fertilisation (IVF) and 
ovarian stimulation for PGD. Awareness of reproductive testing options was very 
variable among the cohort. Th e fi ndings highlight the complexities of reproductive 
decision making for young women who knowingly carry a BRCA mutation, 
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and the dilemmas inherent to reproductive genetic testing when the condition 
being tested for also aff ects a prospective parent. Counselling and psychological 
support for BRCA-positive women and couples concerning reproductive options 
are strongly indicated.
Moff at R, de Geyter C, Myrick ME et al. (2012) Young women with breast 
cancer: how many are actually candidates for fertility preservation? Arch 
Gynecol Obstet 2012 (in press)
Th ere are no data regarding the actual need for fertility preservation (FP) in 
breast cancer (BC) patients. Our study provides a practical needs assessment for 
reproductive medicine by analyzing an unselected cohort of young BC patients. 
Th is assessment considers oncological factors as well as the patient’s obstetrical and 
gynecological history and reproductive outcome after BC diagnosis. We aimed to 
identify how many patients are actually potential candidates for FP and how many 
patients might consequently use their cryopreserved gametes to achieve pregnancy.
Based on a prospective BC database, we analyzed all patients who were 
 40 years at initial diagnosis (time period of diagnosis: 1990-2007; n = 100; 
7.7 % of the entire BC cohort; median age: 35.9 years).
Results: Using an algorithm of exclusion criteria considering disease-specifi c, 
therapy-specifi c and family history characteristics, 36 patients who received 
chemotherapy were identifi ed as potential “classical” candidates for FP. After 
5  years, 22  women were identifi ed as potential candidates for using their 
cryopreserved gametes to achieve pregnancy; the majority of these patients were 
childless (n = 16, 72.7 %) and in their late reproductive years (n = 12, 54.5 %).
Our study demonstrates that in a cohort of young BC patients only a minority 
of women are candidates for FP. Young BC patients who wish to have children in 
the future usually carry risk factors both from oncological and reproductive medicine 
perspective. Due to this high-risk profi le, the rarity of BC in young age and the 
limited number of patients who might actually have opted for FP, these women must 
be off ered timely and multidisciplinary counseling in highly specialized centers.
Liat LG, Jaron R, Liraz O (2012) Are infertility treatments a potential risk 
factor for cancer development? Perspective of 30 years of follow-up. Gynecol 
Endocrinol 2012 (in press)
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Th e aim of the present study was to evaluate the possible risk for cancer 
development in infertile women with over 30  years of follow-up. Cancer 
development was assessed through linkage with the National Cancer Registry 
updated to 31 December 2005 in a cohort of 2431 women who were treated for 
infertility at the Sheba Medical Center in Israel during the period 1964-1974 and 
contributed more than 84,000 women years of follow-up. Standardized incidence 
ratios (SIR) were calculated between the observed cancer cases and the expected 
cancer rates in the general population. Th e mean age at the end of follow-up was 
62.7 years. Eighteen cases of ovarian cancer were observed as compared to 18.1 
expected (SIR = 1.0; 95% CI = 0.59-1.57). For breast cancer, 153 cases were 
observed as compared to 131.9 expected (SIR = 1.16; 95% CI = 0.98-1.36), and 
for endometrial cancer, 30 cases were observed as compared to 17.8 expected cases 
(SIR = 1.69; 95% CI = 1.14-2.41). No excess risk associated with exposure to 
gonadotropins was observed. Infertility was found to be associated with signifi cant 
increased risk for endometrial cancer and borderline increased risk for breast 
cancer. Ovarian cancer risk was not found to be elevated. No signifi cant excess 
risk was associated with treatment with ovulation induction.
Cooley A, Matthews L, Zelivianski S (2012) Eff ect of infertility treatment 
and pregnancy-related hormones on breast cell proliferation in vitro. Hum 
Reprod 27: 146-52
Breast cancer development involves a series of mutations in a heterogeneous 
group of proto-oncogenes/tumor suppressor genes that alter mammary cells to 
create a microenvironment permissive to tumorigenesis. Exposure to hormones 
during infertility treatment may have a mutagenic eff ect on normal mammary 
epithelial cells, high-risk breast lesions and early-stage breast cancers. Our goal 
was to understand the association between infertility treatment and normal and 
cancerous breast cell proliferation.
MCF-10A normal mammary cells and the breast cancer cell lines MCF-7 
[estrogen receptor (ER)-positive, well diff erentiated] and HCC 1937 (ER-negative, 
aggressive, BRCA1 mutation) were treated with the weak ER activator clomiphene 
citrate and hormones that are increased during infertility treatment. Direct eff ects 
of treatment on cell proliferation and colony growth were determined.
While clomiphene citrate had no eff ect on MCF-10A cells or MCF-7 breast cancer 
cells, it decreased proliferation of HCC 1937 versus untreated cells (P = 0.003). 
Estrogen had no eff ect on either MCF-10A or HCC 1937 cells but, as expected, 
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increased cell proliferation (20-100 nM; P  0.002) and colony growth (10-30 nM; 
P < 0.0001) of MCF-7 cells versus control. Conversely, progesterone decreased both 
proliferation (P = 0.001) and colony growth (P = 0.01) of MCF-10A cells, inhibited 
colony size of MCF-7 cells (P = 0.01) and decreased proliferation of HCC 1937 
cells (P = 0.008) versus control. hCG (100 mIU/ml) decreased both proliferation 
(P  0.01) and colony growth (P  0.002) of all three cell lines.
Although these data are preclinical, they support possible indirect estrogenic 
eff ects of infertility regimens on ER-positive breast cancer cells and validate the 
potential protective eff ect of pregnancy-related exposure to hCG.
Boukaidi SA, Cooley A, Hardy A (2012) Impact of infertility regimens on 
breast cancer cells: follicle-stimulating hormone and luteinizing hormone 
lack a direct eff ect on breast cell proliferation in vitro. Fertil Steril 97: 440-4
To examine the impact of hormones used for controlled ovarian hyperstimulation 
(COH) on normal and malignant breast cell growth and proliferation.
In vitro study of cultured normal and malignant breast cell lines.
Academic medical center. None patients. Normal and malignant breast cell 
lines cultured in two- and three-dimensional (2D and 3D) systems and treated 
with follicle-stimulating hormone (FSH), luteinizing hormone (LH), or FSH 
with LH or human chorionic gonadotropin (hCG).
Eff ects of treatment on cell proliferation in 2D culture using the MTS assay 
and on colony growth in 3D culture.
Compared with untreated cells, normal MCF-10A cells showed a decrease in 
proliferation and colony size when exposed to a combination of FSH and hCG. 
Th e HCC 1937 cells treated with FSH and LH also showed a decrease in colony 
growth but no change in proliferation. None of the treatments had an eff ect on 
the proliferation or colony size of the MCF-7 cells.
Follicle-stimulating hormone, LH, and hCG do not appear to cause an 
increase in cell proliferation or colony growth in either normal or malignant 
mammary epithelial cell lines. Th e potential risk for mammary cell transformation 
associated with these agents may be related to indirect endocrine eff ects on breast 
cell physiology.
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Mailliez A, Decanter C, Bonneterre J (2011) Adjuvant chemotherapy for 
breast cancer and fertility: estimation of the impact, options of preservation 
and role of the oncologist. Bull Cancer 98: 741-51
Fifty-two thousand new breast cancers occur each year in France, 7% in patients 
less than 40 years. Th e standard regimens of adjuvant chemotherapy for breast 
cancer now include anthracyclines and taxanes. Th ese therapeutics advances have 
signifi cantly improved the prognosis of these young women who may later wish 
to become mother and have biological off spring. Th e impact of chemotherapy 
on reproductive function should be accurately assessed and the ovarian reserve 
has to be taken into account. Th e estimated risk of chemo-induced amenorrhea 
and infertility has to be balanced with the expected results and risks of methods 
of fertility preservation. Th e place of diff erent options for fertility preservation 
depends on patient age, presence or not of a partner and the time available before 
the initiation of treatment. For these breast cancer patients who will receive 
chemotherapy, new techniques of in vitro oocyte maturation seem promising. 
Even if some ethical and technical issues are unresolved, fertility preservation 
must now be part of the management of these young patients receiving adjuvant 
chemotherapy for breast cancer. Th is new approach must be multidisciplinary 
and complex.
Wallace WH, Anderson RA, Irvine DS (2005) Fertility preservation for young 
patients with cancer: who is at risk and what can be off ered? Lancet Oncol 
6: 209-18
Estimates suggest that by 2010, one in 715 people in the UK will have survived 
cancer during childhood. With increasing numbers of children cured, attention 
has focused on their quality of life. We discuss the causes of impaired fertility 
after cancer treatment in young people, and outline which patients are at risk 
and how their gonadal function should be assessed. With the report of a livebirth 
after orthotopic transplantation of cryopreserved ovarian tissue and the continued 
development of intracytoplasmic sperm injection for men with poor sperm 
quality, we assess established and experimental strategies to protect or restore 
fertility, and discuss the ethical and legal issues that arise.
Peccatori FA, Pup LD, Salvagno F (2012) Fertility Preservation Methods in 
Breast Cancer. Breast Care (Basel) 7: 197-202
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Th anks to the recent advances in reproductive medicine, more and more young 
women with breast cancer may be off ered the possibility of preserving their fertility. 
Fertility can be endangered by chemotherapy, by treatment duration and by 
patient’s age at diagnosis. Th e currently available means to preserve a young 
woman’s fertility are pharmacological protection with gonadotrophin-releasing 
hormone analogues during chemotherapy, and ovarian tissue or oocyte/embryo 
freezing before treatment. New future venues, including in vitro maturation, 
will improve the feasibility and effi  cacy of the fertility preservation methods in 
breast cancer patients.
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